Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Research & Development (2022 - 2025)

Stoke Therapeutics has reported Research & Development over the past 4 years, most recently at $41.7 million for Q4 2025.

  • For Q4 2025, Research & Development rose 78.01% year-over-year to $41.7 million; the TTM value through Dec 2025 reached $137.9 million, up 54.74%, while the annual FY2025 figure was $137.9 million, 54.74% up from the prior year.
  • Research & Development for Q4 2025 was $41.7 million at Stoke Therapeutics, up from $37.7 million in the prior quarter.
  • Over five years, Research & Development peaked at $41.7 million in Q4 2025 and troughed at $18.3 million in Q1 2022.
  • A 4-year average of $24.2 million and a median of $21.5 million in 2023 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: grew 0.81% in 2023 and later surged 78.01% in 2025.
  • Year by year, Research & Development stood at $21.1 million in 2022, then rose by 3.41% to $21.8 million in 2023, then rose by 7.55% to $23.4 million in 2024, then soared by 78.01% to $41.7 million in 2025.
  • Business Quant data shows Research & Development for STOK at $41.7 million in Q4 2025, $37.7 million in Q3 2025, and $25.9 million in Q2 2025.